Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin: The 26-Week Interventional, single-arm ARTEMIS-DM study

• Main Authors: Sethi, Bipin, Al-Rubeaan, Khalid, Unubol, Mustafa, Mabunay, Maria A., Berthou, Baptiste, Pilorget, Valerie, Vethakkan, Shireene R., Frechtel, Gustavo
• Format: Article
• Published: Springer Heidelberg 2022
• Subjects: QP Physiology; RC Internal medicine
• Online Access: http://eprints.um.edu.my/41913/
• Institution: Universiti Malaya

Introduction The efficacy and safety of switching to insulin glargine 300 U/mL (Gla-300) in type 2 diabetes mellitus (T2DM) uncontrolled on basal insulin (BI) has been demonstrated in the North American and Western European populations; however, there is limited data from other geographical regions with different ethnicities. The ARTEMIS-DM study aimed to evaluate the efficacy and safety of Gla-300 in people with T2DM uncontrolled on BI from Asia, Latin America and Middle East Africa. Methods The ARTEMIS-DM was a 26-week, prospective, interventional, single-arm, phase IV study (NCT03760991). Adults with T2DM previously uncontrolled (glycated haemoglobin HbA(1c)] 7.5-10%) on BI were switched to Gla-300. The primary endpoint was change in HbA(1c) from baseline to 26 weeks. Key secondary endpoints were changes in HbA(1c) (week 12), fasting plasma glucose (FPG), self-monitored plasma glucose (SMPG) and BI dose from baseline to week 26. The safety and tolerability of Gla-300 were also assessed. Results A total of 372 (50% male) participants were included, with mean (standard deviation SD]) age 60.9 (10.0) years, duration of diabetes 13.11 (7.48) years and baseline HbA(1c) 8.67 (0.77)% (71.22 8.44] mmol/mol). A total of 222 (59.7%) participants were using insulin glargine 100 U/mL and 107 (28.8%) were using neutral protamine Hagedorn insulin as previous BI. There were clinically significant reductions in mean HbA(1c) (- 0.82%; primary endpoint), FPG and SMPG levels at week 26. With a pre-defined titration algorithm, mean Gla-300 dose increased from 27.48 U (0.35 U/kg) at baseline to 39.01 U (0.50 U/kg) at week 26. Hypoglycaemia events occurred in 20.4% of the participants; 1 (0.3%) participant had a severe hypoglycaemia event. Conclusion In people with T2DM uncontrolled on previous BI, switching to Gla-300 with optimal titration guided by an algorithm was associated with improved glycaemic control and low incidence of hypoglycaemia across multiple geographic regions. ClinicalTrials.gov identifier NCT03760991.